What is Mana.bio?
Mana.bio operates at the intersection of artificial intelligence and biotechnology, specializing in the discovery and optimization of novel, customizable lipid nanoparticles. These LNPs are essential vehicles for the delivery of nucleic acid-based vaccines and therapeutics, which require precise targeting to maximize efficacy while minimizing systemic toxicity. By utilizing a data-driven approach, the company provides a robust platform that streamlines the development of next-generation medical interventions. Its market position is defined by its unique ability to engineer delivery systems that are tailored for specific tissue types, a capability that is increasingly sought after by pharmaceutical giants and biotech developers alike.
How much funding has Mana.bio raised?
Mana.bio has raised a total of $19.5M across 1 funding round:
Angel/Seed
$19.5M
Angel/Seed (2023): $19.5M with participation from The NFX, LionBird, and Andreessen Horowitz
Key Investors in Mana.bio
The NFX
NFX is a venture capital firm that focuses on investing in pre-seed and seed stage startups, aiming to support exceptional founders who are building transformative companies across various sectors.
LionBird
LionBird invests in innovative health-tech startups that aim to transform the healthcare landscape through technology, providing pre-scale capital and support to dedicated teams.
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies.
What's next for Mana.bio?
With this major enterprise-level funding, Mana.bio is poised to transition from its foundational research phase into a more aggressive development and partnership cycle. The strategic roadmap likely includes the expansion of its internal pipeline of therapeutic candidates and the establishment of collaborative agreements with global pharmaceutical entities. As the company continues to refine its AI-driven LNP platform, the focus will shift toward validating these delivery systems in preclinical models, ultimately aiming to shorten the development timelines for complex genetic medicines. The firm's ability to maintain its technological edge in the competitive landscape of AI-enabled drug delivery will be the primary driver of its long-term valuation and industry impact.
See full Mana.bio company page
